Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: J Immunol Regen Med. 2019 Feb 10;5:100015. doi: 10.1016/j.regen.2019.100015

Figure 6. Indoleamine 2,3-dioxygenase (IDO) functions as an extracellular immunomodulator.

Figure 6.

Dendritic cells treated with exogenously supplied IDO enzyme resist LPS activation as quantified by the reduction in IL-12p70 secretion, a maintained level of IL-10 secretion, and a downregulation in surface expression of stimulatory and co-stimulatory markers, generating a phenotype suppressive to T cells.